NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Coronavirus: India reports 1.32L cases; Delta variant blamed for spike
    India

    Coronavirus: India reports 1.32L cases; Delta variant blamed for spike

    Coronavirus: India reports 1.32L cases; Delta variant blamed for spike
    Written by Siddhant Pandey
    Jun 04, 2021, 02:54 pm 3 min read
    Coronavirus: India reports 1.32L cases; Delta variant blamed for spike
    The Delta variant of SARS-CoV-2 is the primary cause of India's second wave, a study has found.

    Despite a slow down in India's grim second wave of COVID-19, the country continues to report a high number of infections and deaths. India on Friday reported 1.32 lakh new COVID-19 cases, along with over 2,700 deaths. A study has now claimed that the Delta variant of the coronavirus SARS-CoV-2, first detected in India, is responsible for the second wave. Here are more details.

    India's tally reaches 2.85 crore; 3.40 lakh dead

    According to the Union Health Ministry, till Friday morning, India reported a total of 2,85,74,350 COVID-19 cases. The death toll has reached 3,40,702. So far, 2,65,97,655 patients have recovered, while 16,35,993 cases involve active infections. In the past 24 hours alone, India recorded 1,32,364 new infections, 2,07,071 more discharges, and 2,713 fresh fatalities. 22,41,09,448 vaccine doses have been administered so far.

    24K new cases in Tamil Nadu

    Maharashtra reported 15,229 new COVID-19 cases along with 25,617 more recoveries. Karnataka, the second worst-hit state after Maharashtra, reported 18,324 new cases and 24,036 discharges. Meanwhile, the third worst-hit Kerala added 18,853 new cases and 26,569 recoveries. Tamil Nadu, the fourth worst-hit state, reported 24,405 new cases and 32,221 recoveries. Andhra Pradesh reported 11,421 new cases and 16,223 recoveries.

    Delta variant primary cause of second wave: Study

    The Delta variant of the coronavirus (B.1.617.2 strain) is the primary cause of the second wave of COVID-19 in India, a study has found. The study was conducted by scientists of INSACOG and the National Centre for Disease Control (NCDC). The study found that the Delta variant is 50% more transmissible than the Alpha variant (B.1.1.7) and that India has 12,200 'Variants of Concern'.

    Prior infections can provide significant protection from reinfection: Study

    Separately, a study of care home residents and staff by University College London (UCL) scientists found that a prior COVID-19 infection can reduce the risk of reinfection by approximately 85%. Among staffers, those who had been infected were 60% less likely to be reinfected.

    Only 7.5% vaccine doses administered at private centers

    On a related note, private vaccination centers account for only 7.5% of total doses administered, despite having a 25% quota as per the Centre's vaccination policy. A relatively higher proportion of private center vaccinations was observed in a few urban pockets, however, in almost 80% of districts, 95% of doses were administered by the public sector, an analysis by The Times of India found.

    India among beneficiaries of US vaccine aid

    Meanwhile, tnhe United States has announced a plan to distribute an initial 25 million vaccine doses and India is among the beneficiaries. Additionally, Reliance Industries Ltd's R&D arm has proposed the use of Niclosamide to treat COVID-19. The antiviral drug was used to treat patients in the 2003-04 SARS outbreak and its Phase II clinical trials have already been approved.

    Company commercially launches self-testing kit

    Biotechnological firm Mylab Discovery Solutions on Thursday commercially launched its COVID-19 self-test kit, called 'CoviSelf'. Reportedly, Biological E has started at-risk manufacturing of its recombinant protein COVID-19 vaccine, Corbevax, which is slated to be the most affordable vaccine.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Ministry of Health and Family Welfare
    Coronavirus

    Ministry of Health and Family Welfare

    India records 425 COVID-19 cases, 3 deaths in 24 hours COVID-19
    COVID-19: India registers 490 new cases, 2 deaths COVID-19
    India reports 535 fresh COVID-19 cases, 5 deaths COVID-19
    COVID-19: India records 552 new cases, 6 deaths COVID-19

    Coronavirus

    What is 'Arcturus,' new COVID-19 variant with different symptom COVID-19
    IMA lists 3 reasons behind COVID-19 surge in India COVID-19
    Nationwide COVID-19 preparedness mock drill at hospitals today, tomorrow COVID-19
    States adopt strict measures amid spike in COVID-19 cases COVID-19

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023